Navigation Links
Pneumonia Drug Promising Against Form of Muscular Dystrophy
Date:11/12/2009

In studies with mice, pentamidine combats genetic defects that lead to myotonic dystrophy

THURSDAY, Nov. 12 (HealthDay News) -- Researchers report that a drug used to treat pneumonia might serve as an effective treatment against a type of muscular dystrophy.

They tested the drug pentamidine in mice and found that it appears to combat genetic defects that lead to type 1 myotonic dystrophy, one of nine types of muscular dystrophy. The muscle-wasting condition is also known as DM1 and Steinart's disease.

The levels used in mice would be poisonous in humans, but University of Oregon chemist J. Andrew Berglund, whose lab tested the drug, said it could be modified.

Pentamidine is approved to treat several conditions, including a severe type of pneumonia in people with compromised immune systems, some yeast infections and sleeping sickness.

"Pentamidine is an exciting lead compound because it is relatively easy to chemically modify, and hopefully one of these modified compounds could lead to a safe, long-term treatment for DM1 in the future," said Berglund.

The study, funded in part by the U.S. National Institutes of Health and the Muscular Dystrophy Association, was published in the Nov. 3 issue of Proceedings of the National Academy of Sciences.

More information

Learn more about muscular dystrophy from the National Institutes of Health.



--Randy Dotinga



SOURCE: University of Oregon, press release, Nov. 6, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Page: 1

Related medicine news :

1. Zinc Helps Elderly Ward Off Pneumonia
2. Heart attacks/pneumonia falls short of national goals
3. Emergency Care for Heart Attacks, Pneumonia Fails to Meet Goals
4. Cethromycin achieves all endpoints in second pivotal Phase III Trial for treatment for pneumonia
5. Pneumonia Vaccine Is Keeping Kids Healthier
6. Treating Childhood Pneumonia at Home Could Save Lives in Developing Countries
7. Childrens Hospital scientists identify possible target for prevention and treatment of pneumonia
8. Community-Based Staph Pneumonia More Common Than Thought
9. TB Drug Treatment Can Lead to Severe Pneumonia
10. Antipsychotic drugs increase risk of developing pneumonia in elderly
11. Bayer/Schering-Plough/Shionogis Avelox Has Advantages Over Levofloxacin in the Treatment of Community-Acquired Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 22, 2017 , ... Wash Tower Ltd. has released a series ... Wash Tower, the world's first standalone constant pressure bidet. , The videos in the ... at https://www.washtower.com as well as on its social media pages. , Each ...
(Date:3/22/2017)... ... 2017 , ... The Rett Syndrome Research Trust (RSRT) announced ... afflicts 350,000 individuals worldwide. Rett Syndrome is caused by alterations in a ... Following a normal infancy, Rett Syndrome takes effect in toddlerhood depriving children ...
(Date:3/22/2017)... ... March 22, 2017 , ... Drs. Jennifer Houck, Lauren Smith, Heather ... accept new patients in need of skilled pediatric dentistry in Rock Hill, ... offers pediatric patients routine treatments, including cavities, sealants and fluoride applications, in a comfortable ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Burke Medical ... to translate advances in basic neuroscience at the BMRI labs into new and ... to improve movement, vision, and cognition impaired by stroke, traumatic brain injury, cerebral ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... ... imaging core lab with extensive therapeutic experience and operational excellence in oncology clinical ... immuno-oncology clinical trial for the treatment of non-small cell lung cancer and small ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... , March 22, 2017 Under the ... pharmaceutical packaging market size increased year by year ... 2017 to 2021, the market size will maintain ... expected to outnumber RMB140 billion in 2021, thanks ... rapid development of biological agents and supporting policies. ...
(Date:3/22/2017)... -- ImaginAb Inc. today announced the appointment of Martyn Coombs ... chairman of ImaginAb, said "At ImaginAb we have exciting science and ... to our business, particularly in commercializing and making step changes in ... can realize our potential." ... Mr. Coombs is a recognized industry leader in nuclear medicine ...
(Date:3/22/2017)... 22, 2017  CANTEL MEDICAL CORP. (NYSE: CMD ... and CEO, will be presenting at the 16 th ... Central Hotel in New York . The ... 3:00 p.m. ET. In addition, management will be available for ... live audio webcast will be available via the investor relations ...
Breaking Medicine Technology: